Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun 25:8:17.
doi: 10.1186/1745-6215-8-17.

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation

Rachel M Cooney  1 , Bryan F Warren, Douglas G Altman, Maria T Abreu, Simon P L Travis
Affiliations

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation

Rachel M Cooney et al. Trials. .

Abstract

Clinical trials on novel drug therapies require clear criteria for patient selection and agreed definitions of disease remission. This principle has been successfully applied in the field of rheumatology where agreed disease scoring systems have allowed multi-centre collaborations and facilitated audit across treatment centres. Unfortunately in ulcerative colitis this consensus is lacking. Thirteen scoring systems have been developed but none have been properly validated. Most trials choose different endpoints and activity indices, making comparison of results from different trials extremely difficult. International consensus on endoscopic, clinical and histological scoring systems is essential as these are the key components used to determine entry criteria and outcome measurements in clinical trials on ulcerative colitis. With multiple new therapies under development, there is a pressing need for consensus to be reached.

PubMed Disclaimer

References

    1. Symmons D, Tricker K, Harrison M, Roberts C, Davis M, Dawes P, Hassell A, Knight S, Mulherin D, Scott DL. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized control clinical trial. Rheumatology (Oxford) 2006;45:558–565. doi: 10.1093/rheumatology/kei169. - DOI - PubMed
    1. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J, Sutherland LR. A Review of Activity Indices and Efficacy Points for Clinical Trials of Medical Therapy in Adults with Ulcerative Colitis. Gastroenterology. 2007;132:763–786. doi: 10.1053/j.gastro.2006.12.038. - DOI - PubMed
    1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;ii:1041–8. - PMC - PubMed
    1. Powell-Tuck J, Day DW, Bucknell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533–7. doi: 10.1007/BF01296733. - DOI - PubMed
    1. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987;317:1625–1629. - PubMed